The inhibition of the EZH2-TPH1-5-HT-5-HT7 axis was effective in regressing gemcitabine-resistant pancreatic cancer growth in vivo, suggesting that the axis may be a potential therapeutic target for the treatment of drug-resistant PDAC. The gene discussed is TPH1; the disease is familial pancreatic carcinoma.